The association between primary antiretroviral resistance and HAART virologic failure in a developing set

AIDS Research and Human Retroviruses

Volumn 27, Issue 3, 2011, Pages 251-256

  Gagliani, Luiz Henrique ^a,b   Alkmim Maia, Wagner T ^a   Sá Filho, Dercy ^b   Janini, Luiz Mario ^a   Sucupira, Maria Cecilia ^a   Caseiro, Marcos Montani ^b   Diaz, Ricardo Sobhie ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Centro Universitario Lusiada   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BISEXUALITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CLADISTICS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GENOTYPE; HETEROSEXUAL FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; LABORATORY TEST; MALE; MALE HOMOSEXUAL; MUTATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD; VIRUS STRAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 79952587399     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0150     Document Type: Article

References (27)

1. Munerato P, Sucupira MC, Oliveros MP, Souza DF, Pereira AA, Janini LM, et al.: HIV-1 Antiretroviral resistance muta-tions in subtypes B C and F in the city of São Paulo Brazil. AIDS Res Hum Retroviruses 2010; 26 (3): 265-273.
2. Inocencio LA, Pereira AA, Sucupira MC, Fernandez JC, Jorge CP, Souza DF, et al.: Brazilian Network for HIV Drug Resistance Surveillance: A survey of individuals recently diagnosed with HIV. J Int AIDS Soc 2009;12:20.
3. Brindeiro RM, Diaz RS, Sabino EC, Morgado MG, Pires IL, Brigido L, et al.: Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): A survey of chronically in-fected individuals. AIDS 2003;17:1063-1069. (Pubitemid 36549719)
4. Pedroso C, Queiroz AT, Alcantara LC, Drexler JF, Diaz RS, Weyll N, and Brites C: High prevalence of primary anti-retroviral resistance among HIV-1-infected adults and chil-dren in Bahia, a northeast state of Brazil. J Acquir Immune Defic Syndr 2007;45:251-253. (Pubitemid 46869822)
5. Varella RB, Ferreira SB, de Castro MB, Zalis MG, and Tavares MD: Human immunodeficiency virus type 1 pro-tease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil. J Med Virol 2007;79:1033-1039. (Pubitemid 47015400)
6. Sucupira MC, Caseiro MM, Alves K, Tescarollo G, Janini LM, Sabino EC, et al.: High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS 2007;21:116-128. (Pubitemid 46394455)
7. de Medeiros LB, Lacerda HR, Cavalcanti AM, and de Albu-querque Mde F: Primary resistance of human immunodefi-ciency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Mem Inst Oswaldo Cruz 2006;101:845-849. (Pubitemid 46131332)
8. Diaz RS, De Souza RS, Sucupira MC, Cavalieri E, Ribeiro KM, Mondini L, et al.: Lower prevalence of primary anti-retroviral resistance among clade C infected individuals as compared to clade B in South Brazil's emerging clade C HIV-1 epidemic. XVII International AIDS Conference, Mexico City, Mexico 3-8 August, 2008.
9. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, et al.: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus in-fection. J Virol 2008;82:5510-5518. (Pubitemid 351705258)
10. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al.: Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18:1683-1689. (Pubitemid 39095785)
11. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, et al.: Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004;9:415-421. (Pubitemid 38878757)
12. Jain V, Sucupira MC, Deeks S, Liegler T, Pilcher CD, Grant R, et al.: Persistence of transmitted drug-resistance mutations in patients with acute HIV. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8-11 Feb-ruary, 2009.
13. Soares MA, De Oliveira T, Brindeiro RM, Diaz RS, Sabino EC, Brigido L, et al.: A specific subtype C of human immu-nodeficiency virus type 1 circulates in Brazil. AIDS 2003; 17:11-21. (Pubitemid 36106294)
14. De Sa Filho DJ, Sucupira MC, Caseiro MM, Sabino EC, Diaz RS, and Janini LM: Identification of two HIV type 1 circu-lating recombinant forms in Brazil. AIDS Res Hum Retro-viruses 2006;22:1-13. (Pubitemid 43201511)
15. Guimaraes ML, Eyer-Silva WA, Couto-Fernandez JC, and Morgado MG: Identification of two new CRF-BF in Rio de Janeiro State, Brazil. AIDS 2008;22:433-435.
16. Santos AF, Sousa TM, Soares EA, Sanabani S, Martinez AM, Sprinz E, et al.: Characterization of a new circulating re-combinant form comprising HIV-1 subtypes C and B in southern Brazil. AIDS 2006;20:2011-2019. (Pubitemid 44611054)
17. Sa Filho DJ, Sanabani S, Diaz RS, Munerato P, Brunstein A, Fusuma E, et al.: Analysis of full-length human immunode-ficiency virus type 1 genome reveals a variable spectrum of subtypes B and F recombinants in São Paulo, Brazil. AIDS Res Hum Retroviruses 2005;21:145-151. (Pubitemid 40354356)
18. Leal E ML, Janini LM, and Diaz RS: Evolutionary dynamics of HIV-1 BF and CB recombinants and its parental coun-terparts in South America. Retrovirol Res Treat 2008;1:1-14.
19. de Sa-Filho DJ, Soares Mda S, Candido V, Gagliani LH, Cavaliere E, Diaz RS, and Caseiro MM: HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil. AIDS Res Hum Retroviruses 2008;24:347-353. (Pubitemid 351457749)
20. Caseiro MM, Golega AA, Etzel A, and Diaz RS: Character-ization of virologic failure after an initially successful 48-week course of antiretroviral therapy in HIV/AIDS out-patients treated in Santos, Brazil. Braz J Infect Dis 2008; 12:162-166.
21. Calazans A, Brindeiro R, Brindeiro P, Verli H, Arruda MB, Gonzalez LM, et al.: Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005;191:1961-1970. (Pubitemid 40705405)
22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4:e4724.
23. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al.: Reduced antiretroviral drug suscepti-bility among patients with primary HIV infection. JAMA 1999;282:1142-1149. (Pubitemid 29441958)
24. Accetturi CA, Pardini R, Novaes Pinto GH, Turcato G Jr, Lewi DS, and Diaz RS: Effects of CCR5 genetic polymor-phism and HIV-1 subtype in antiretroviral response in Bra-zilian HIV-1-infected patients. J Acquir Immune Defic Syndr 2000;24:399-400.
25. Diaz RS, Vasconcelos L, Hayden RL, Tenore S, and Turcato G Jr: Palacios R, Sucupira MC. Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil. J Acquir Immune Defic Syndr 2008;47:399-401. (Pubitemid 351619430)
26. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7557. (Pubitemid 351830056)
27. Weber J, Henry KR, Arts EJ, and Quinones-Mateu ME: Viral fitness: Relation to drug resistance mutations and mecha-nisms involved: Nucleoside reverse transcriptase inhibitor mutations. Curr Opin HIV AIDS 2007;2:81-87. (Pubitemid 46947939)